A Phase 3 interventional study of IIV-HD (standalone) and NVXC19 (EU licensed, standalone) in Immunization, Healthy Volunteers and COVID-19 Immunization, sponsored by Sanofi. Recruiting at 2 sites in Poland. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Sanofi · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Influenza, Human by Sanofi — 4 open to participants now, 6 under way, 1 of them phase 3. Influenza, Human · Sanofi.
Among the 139 studies in Influenza, Human by Sanofi, this one is the 5th largest by planned enrollment of the 126 interventional ones that give a count, is one of 5 that started in 2026, is one of 35 in phase 3, and was the 139th registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →4 of the 139 studies in Influenza, Human by Sanofi are open now, in 3 countries. Recruiting first, the newest first:
Sanofi · Sites in Korea, Republic of
Ages 65+ · Healthy volunteers
Sanofi · Sites in United States
Ages 18+ · Healthy volunteers
Sanofi · Sites in Korea, Republic of
Ages 65+ · Healthy volunteers
By country, each count listing its studies:
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 47 · Phase 3 35 · Phase 4 33
First in 2003; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 6,000 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 305 across the 126 interventional studies, 1,001 across the 13 observational. Of the 133 that completed or were terminated, 73 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
2 of the studies in Influenza, Human by Sanofi that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06907511SanofiStudy to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older | 2026-12-01 |
| NCT07516418SanofiStudy of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age | 2027-04-04 |
Add all 2 to your calendar (.ics) → With an account.
Among the 139 studies in Influenza, Human by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety and immunogenicity of IIV-HD + NVXC19 vaccine compared to seasonal influenza vaccine (IIV-HD) and COVID-19 vaccine, adjuvanted (NVXC19) coadministered in adult participants 60 years of age and older. Placebo will be coadministered in the IIV-HD + NVXC19 study group to control for the number of injections and to maintain observer-blinding. Thus, each participant will receive 2 injections at enrollment, one in each deltoid muscle.
Study details include:
The criteria were revised on the registry on Nov 13, 2026. See what changed
Inclusion criteria
Inclusion criteria to be checked at Screening Visit:
Exclusion criteria Exclusion Criteria to be Checked at Screening Visit and at Visit 1 (D01) Medical conditions
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
IIV-HD and NVXC19 co-administered in opposite deltoid muscles
Drug: IIV-HD (standalone) · Drug: NVXC19 (EU licensed, standalone)
IIV-HD + NVXC19 and Placebo co-administered in opposite deltoid muscles
Drug: IIV-HD + NVXC19 combination · Drug: Placebo, normal saline
Pharmaceutical form: Suspension Route of administration: Intramuscular injection
Pharmaceutical form: Dispersion Route of administration: Intramuscular injection
Pharmaceutical form: Suspension Route of administration: Intramuscular injection
Pharmaceutical form: Solution Route of administration: Intramuscular injection
Antibody titers against for each of the 3 influenza vaccine strains(in a subset of participants)
Geometric mean (GMT) of antibody titers measured by hemagglutination inhibition (HAI)
Time frame: At Day 28 after vaccination
Antibody titers against SARS-CoV-2 specific variant(in a subset of participants)
Geometric mean (GMT) of antibody titers measured by pseudovirus neutralization test (PNT)
Time frame: At Day 28 after vaccination
Presence of solicited injection site reactions for 8 days, including the day of vaccination (Main subset of participants)
Number of participants with solicited injection site reactions pre-listed in the participant diary and case report form (CRF)
Time frame: Up to 8 each days after vaccination
Presence of solicited systemic reactions for 8 days, including the day of vaccination (Main subset of participants)
Number of participants with solicited systemic reactions pre-listed in the participant diary and case report form (CRF)
Time frame: Up to 8 each days after vaccination
Presence of immediate adverse events after vaccination
Number of participants with immediate adverse events (AEs). Immediate adverse events are any unsolicited systemic adverse events within 30 minutes after vaccination
Time frame: Within the 30 minutes after vaccination
Presence of unsolicited adverse events
Number of participants with unsolicited adverse events (AEs) for 28 days, including the day of vaccination
Time frame: Up to 28 days after vaccination
Presence of all medically attended adverse events
Number of participants with medical attended adverse events (MAAEs) for 180 days, including the day of vaccination
Time frame: Up to 180 days after vaccination
Presence of related medically attended adverse events linked to predefined potential immune-mediated diseases
Number of participants with medical attended adverse events (MAAEs) linked to predefined potential immune-mediated diseases (PIMDs) following the study vaccination
Time frame: From Day 181 through 12 months following study vaccination
Presence of all adverse events of special interest
Number of participants with adverse events of special interest (AESIs) for 180 days, including the day of vaccination
Time frame: Up to 180 days after vaccination
Presence of all serious adverse events
Number of participants with serious adverse events (SAEs) for 180 days, including the day of vaccination
Time frame: Up to 180 days after vaccination
Presence of related serious adverse events
Number of participants with serious adverse events (SAEs) from D181 through 12 months following the last study vaccination
Time frame: From Day 181 through 12 months following study vaccination
Presence of related adverse events of special interest
Number of participants with adverse events of special interest (AESIs) from D181 through 12 months following the last study vaccination
Time frame: From Day 181 through 12 months following study vaccination
Presence of related medical attended adverse events linked to predefined potential immune-mediated diseases that meet the criteria for serious adverse events
Number of patients with medical attended adverse events (MAAES) linked to predefined potential immune-mediated diseases (PIMDs) meets criteria for serious adverse events (SAEs) from D181 through 12 months following the last study vaccination
Time frame: From Day 181 through 12 months following study vaccination
Presence of adverse events leading to study discontinuation throughout the study
Number of participants with adverse events lead to study discontinuation
Time frame: From Day 01 through 12 months
Influenza seroconversion status after vaccination for each of the 3 influenza vaccine strains
Percentage of participants Seroconversion is defined by: pre-injection antibody titer \< 10 \[1/dil\] at D01 and post-injection antibody titer ≥ 40 \[1/dil\] at D29, or pre-injection antibody titer ≥ 10 \[1/dil\] at D01 and a ≥ 4-fold increase in titer at D29
Time frame: At Day 29
SARS-CoV-2 seroresponse status after vaccination
Percentage of participantsSeroresponse to SARS-CoV-2 is defined by: pre-injection antibody titer \< LLOQ \[1/dil\] and post-injection antibody titer ≥ 4\*LLOQ \[1/dil\] at D29, or pre-injection antibody titer ≥ LLOQ \[1/dil\] at D01 and a ≥ 4-fold increase in titer \[1/dil\] at D29
Time frame: At Day 29
Neutralizing antibody titers measured by neutralization test (NT) against each of the 3 influenza vaccine strains before and after vaccination (in a subset of participants)
Neutralizing antibody titers \[1/dil\]
Time frame: At Day 01 and Day 29
Individual neutralizing antibody titer ratio measured by neutralization test NT against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)
Individual neutralizing titers ratio Day 29/Day 01
Time frame: At Day 01 and Day 29
Neutralizing antibody titer against each of the 3 influenza vaccine strains after vaccination(in a subset of participants)
Percentage of participants with neutralization test (NT) titer ≥ 10 (1/dil)
Time frame: At Day 29
Neutralizing antibody titer against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)
Percentage of participants with neutralization test (NT) titer ≥ 20 (1/dil)
Time frame: At Day 29
Neutralizing antibody titer against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)
Percentage of participants with neutralization test (NT) titer ≥ 40 (1/dil)
Time frame: At Day 29
Neutralizing antibody titer against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)
Percentage of participants with neutralization test (NT) titer ≥ 80 (1/dil)
Time frame: At Day 29
Fold increase in neutralization test antibody titer against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)
Percentage of participants fold increase is defined in neutralization test (NT) antibody titer \[post/pre\] ≥ 2-fold rise from Day 01 to Day 29
Time frame: At Day 29
Fold increase in neutralization test antibody titer against each of the 3 influenza vaccine strains after vaccination (in a subset of participants)
Percentage of participants fold increase is defined in neutralization test (NT) antibody titer \[post/pre\] ≥ 4-fold rise from Day 01 to Day 29
Time frame: At Day 29
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Oct 2026 (actual). Primary completion is estimated for Dec 2027, 14 months after the start.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's planned 14 months is above that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.